TOI Earnings Prediction
The chart below shows how TOI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TOI sees a +11.53% change in stock price 10 days leading up to the earnings, and a -29.32% change 10 days following the report. On the earnings day itself, the stock moves by +2.86%. This data can give you a slight idea of what to expect for the next quarter's release.
TOI Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
99.90M
21.78%
1.34%
Gross Margin
12.81%
-26.42%
9.77%
Operating Margin
-13.87%
-18.27%
-16.45%
Net Margin
-16.13%
-24.02%
2.74%
EPS
-0.18
-5.26%
5.88%
No Data Available
TOI Earnings Analysis
The Oncology Institute, Inc. Common Stock Corporation (TOI.O) Earnings Conference Call
Positive
Strong Revenue Surge: Overall, revenue grew 21.8% in the third quarter compared to the prior year period, driven by an exceptional oral drug revenue growth of approximately 80%.
Third Quarter Revenue Increase: Consolidated revenue for the third quarter 2024 was $99.9 million, an increase of 21.8% compared to Q3 2023 and a 1.3% increase compared to Q2 2024.
Gross Profit Increase: Gross profit in Q3 2024 was $14.4 million, an increase of 10.3% compared to Q2 2024, attributed to improved IV margins.
SG&A Expense Improvement: SG&A expenses were $28.2 million in Q3 2024, an improvement of 560 basis points compared to Q3 2023, representing 28.2% of revenue, improving 820 basis points from Q3 2023.
New Capital Contracts Signed: We signed 13 new capital contracts across the organization year-to-date, contributing to our growth momentum.
Negative
Third Quarter Revenue Decline: Consolidated revenue for the third quarter 2024 was $99.9 million, a decrease of 1.3% compared to Q2 2024.
Operational Loss Stability: Loss from operations for Q3 2024 was $13.9 million, flat compared to Q3 2023.
Net Loss Improvement: Net loss for Q3 2024 was $16.1 million, an improvement of $1.3 million compared to Q3 2023.
Adjusted EBITDA Comparison: Adjusted EBITDA for Q3 2024 was negative $8.2 million compared to negative $5.3 million in Q3 2023.
NASDAQ Share Price Warning: The company received a notice from NASDAQ indicating that its share price had fallen below the $1 threshold for 30 consecutive business days.
TOI FAQs
How does TOI typically perform around its earnings report dates?
Is The Oncology Institute, Inc. (TOI) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
TOI Earning Call Sentiment
The Oncology Institute, Inc. (TOI) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
TOI.O
-4.27%Positive
The earnings call summary presents a mixed outlook. Positive aspects include increased revenue, improved gross margins, and new contracts, but these are countered by compliance risks with NASDAQ and ongoing losses. The absence of significant questions in the Q&A suggests no major concerns, but the stock price compliance issue and lack of strong earnings guidance temper enthusiasm. With no clear market cap, the reaction is likely neutral, balancing the positives and negatives.
